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Introduction
TNF-α plays a central role in many forms of liver injury (1–3) and
hence information on signaling of hepatocellular cell death by TNF-α
may be of therapeutic relevance. The signaling mechanism mediating
the intracellular effects of TNF-α is complex and can lead to multiple
responses, including proliferation, inflammation, or cell death. The
cytotoxic effects of TNF-α are the result of the generation of death sig-
nals that originate from the binding of TNF-α to the TNF-α–R1 recep-
tor, a typical death receptor with a 60– to 80–amino acid cytoplasmic
sequence known as the death domain. Research in this area has
unveiled complex protein-protein interactions, recruitment of signal-
ing intermediates, and activation of proteins that mediate the apop-
totic effect of TNF-α (4, 5). Ceramide has emerged as a putative sig-
naling lipid mediator that plays a role in the stress response, cell death,
and TNF-α signaling (6–9). Ceramide levels can increase by de novo
synthesis through activation of serine-palmitoyl transferase, the rate-
limiting enzyme in ceramide synthesis, or ceramide synthetase (10, 11).
However, the hydrolysis of sphingomyelin upon activation of sphin-
gomyelinases (SMases) constitutes an effective means for the rapid
generation of ceramide (8, 9). The binding of TNF-α to its plasma
membrane receptor TNF-α–R1 results in the activation of two major
types of SMases: a neutral SMase (NSMase), with an optimum pH
around 7.5, which is membrane bound and Mg2+ dependent; and an
acidic SMase (ASMase), with an optimum pH of about 4.8, which is
further subclassified into two isoforms, an endosomal/lysosomal
ASMase and a secretory Zn2+-dependent ASMase (8, 9, 12, 13).
While activation of these enzymes may generate ceramide at dif-
ferent cellular sites that mediate the diverse effects of TNF-α, their
role in apoptosis is not well established. Thus, NSMase has been
reported to be involved in the stress response mediating the cytotoxic
effects exerted by chemotherapeutic agents (14), whereas ASMase
has been shown to play an essential role in ionizing radiation–medi-
ated cell death (15, 16) as well as in the developmental death of
oocytes (17). In addition, the factor associated with NSMase activa-
tion, an adaptor protein involved in NSMase activation, has been
shown to contribute to TNF-α–induced fibroblast apoptosis (18),
although the role of NSMase ablation itself in TNF-α–induced apop-
tosis remains unknown. On the other hand, the role of ASMase in
Fas-induced cell death appears to be restricted to hepatocytes, as the
absence of ASMase in hepatocytes has been shown to confer resis-
tance to Fas-mediated cell death (19, 20), while other cell types from
ASMase knockout mice are sensitive to Fas (19). Moreover, we have
recently demonstrated that ASMase plays a significant role in hepa-
tocellular apoptosis and liver damage induced by TNF-α (21).
The liver plays a prominent role in the synthesis and consumption
of S-adenosyl-L-methionine (SAM, also abbreviated as “AdoMet”),
which functions as the one-carbon donor for methylation of DNA,
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RNA, and proteins and in the synthesis of biogenic amines and glu-
tathione (GSH) (22–24). Furthermore, SAM is also required for DNA
and RNA methylation in mitochondria and as an intermediate in the
biosynthesis of ubiquinone and for sterol methylation (25, 26). SAM
is synthesized from methionine and ATP by methionine adenosyl-
transferases (MATs). In mammals there are three known MAT iso-
forms (MAT I, MAT II, and MAT III) (23, 27, 28); MAT I and MAT III
are a tetramer and a dimmer, respectively, of the same α1 subunit, a
43.7-kDa polypeptide encoded by the gene MAT1A, which is exclu-
sively expressed in adult liver (23). MAT2A, on the other hand, is
ubiquitously expressed and encodes a catalytic subunit (α2) found
in a native MAT isoenzyme (MAT II) in association with a regulato-
ry β subunit (29). In the liver, impairment of MAT I/III results in
lowered SAM levels, which contributes to the progression of liver
injury in experimental models and in patients with alcohol- or virus-
induced cirrhosis (23, 30–33). Indeed, the most compelling evidence
for the relevance of hepatic SAM has been recently documented with
the development of MAT1A knockout mice (34). This paradigm
illustrates the devastating consequences of chronic hepatocellular
SAM depletion, which enhances the susceptibility of the liver to oxi-
dant-induced cell death, metabolic disturbances, and spontaneous
hepatocellular carcinoma (34, 35).
A common strategy for investigating the cellular effects of
ceramide has been the incubation of cells with exogenous SMases,
cell-permeable analogs, or natural ceramide, which has revealed a
wide spectrum of responses ranging from cell cycle arrest to prolif-
eration, oxidative stress, apoptosis, and gene regulation (6, 8, 21, 36,
37). As for the effect on gene regulation, membrane-permeant
ceramide analogs (C2 and C6) as well as exogenous NSMase have
been shown to modulate the expression of specific genes such as
cytochrome P450 2C11, α1-acid glycoprotein, or γ-glutamylcysteine
synthetase (γ-GCS) in rat hepatocytes, mimicking the effects of inter-
leukin-1 or TNF-α (36, 37). In addition, we have recently reported
that the cell-permeable ceramide C2 downregulated MAT1A expres-
sion in H35 rat hepatoma cells (38). Thus, the present study was
undertaken to examine the regulation of MAT1A by individual
SMases, namely Bacillus cereus NSMase (bNSMase) and human pla-
centa ASMase (hASMase), previously characterized in rat hepato-
cytes (37), with the ultimate goal of assessing the contribution of
ASMase to the regulation of MAT1A expression and to test the ther-
apeutic role of SAM in TNF-α–induced fulminant liver failure.
Methods
Hepatocyte isolation and incubation with SMases and glycosphingolipids.
ASMase knockout mice (C57BL/6 strain) were propagated using
heterozygous breeding pairs (a generous gift from R. Kolesnick,
Laboratory of Signal Transduction, Memorial Sloan-Kettering
Cancer Center, New York, New York, USA; and E. Gulbins, Uni-
versity of Duisburg-Essen, Essen, Germany) and were genotyped
as described previously (21). Hepatocytes from male Sprague-
Dawley rats (200–300 grams) or male mice (8–12 weeks old) were
isolated by collagenase perfusion with flow rates of 16–18 ml/min
and 7–9 ml/min, respectively, and were cultured at a density of 2 × 106
cells on 60-mm dishes coated with rat tail collagen. Rat or mouse
hepatocytes were incubated with recombinant human TNF-α
(15–280 ng/ml; Preprotech EC, London, United Kingdom) or
exogenous SMases (Sigma-Aldrich, St. Louis, Missouri, USA) by
dilution of concentrated hASMase (250 U/0.55 ml in 50% glycerol,
25 mM potassium phosphate, pH 4.5, 0.1% Triton X-100, and 0.05
mM PMSF) and bNSMase (100 U/ml in 50% glycerol and 50 mM
Tris-HCl, pH 7.5) with culture medium to a concentration of
0.1–1.0 U/ml as described previously (37). Some cultures were pre-
treated with D-threo-1-phenyl-2-decanoylamino-3-morpholino-
propanol HCl (D-threo-PDMP), N-butyldeoxynojirimycin, bafilo-
mycin A1, chloroquine, or mannose 6-phosphate (M 6-P) before
the addition of TNF-α or hASMase. Alternatively, cells were incu-
bated with cell-permeable ceramide (C2 or C6), ganglioside GD3
(GD3), ganglioside GM3 (GM3), glucosylceramide, lactosylce-
ramide, or lyso-glucosylceramide (1–5 µM) (Matreya, Pleasant
Gap, Pennsylvania, USA) in ethanol (0.1%). In addition, cells were
incubated with the natural ceramide C16 in dodecane/ethanol
(2:98 [volume/volume]; 0.05% final concentration) or solvent only
as a control. The experimental protocols met the guidelines of and
were approved by the Animal Care Committee of the Hospital
Clinic-Universidad de Barcelona.
Real-time PCR. MAT1A and MAT2A mRNA levels were determined
by real-time RT-PCR analyses using a LightCycler and a Faststart
SYBR Green I DNA quantification kit (Roche, Mannheim, Germany)
following the manufacturer’s protocol. cDNA was prepared from
total RNA (2 µg) at 50°C for 50 minutes using random hexamers and
the SuperScript III First-Strand Synthesis System for RT-PCR (Invit-
rogen, Carlsbad, California, USA) following the manufacturer’s pro-
tocol. The primers used were: MAT1A, forward, 5′-ATGGACCT-
GTGGATGGC-3′, and reverse, 5′-TGGCCTCCAGTGTTATGT-3′;
MAT2A, forward, 5′CCATGAGGCGTTCATCG-3′, and reverse, 5′-
GCGTAACCAAGGCAATG-3′; 18S, forward, 5′-GGGGAATCAGGG-
TTCGATT-3′, and reverse, 5′-GCGCCGGTCCAAGAATTTCA-3′. The
second-derivative maximum method was taken to determine the
crossing points automatically for individual samples, and relative
amounts of target genes were calculated based on the crossing-point
analysis. The result was expressed as a ratio of product copies to
copies of housekeeping gene 18S from the same RNA.
Northern blot. MAT1A and MAT2A mRNA levels were also deter-
mined by Northern blot analyses of total RNA isolated using the Tri-
zol reagent (Gibco/BRL, Grand Island, New York, USA). Ten micro-
grams of RNA were separated by electrophoresis under denaturing
conditions and were transferred onto Hybond-XL nylon membranes
(Amersham Biosciences, Uppsala, Sweden) and hybridized to ran-
dom-primed 32P-labeled cDNA probes.
MAT I/III protein levels. Samples were resolved by 12.5% SDS-PAGE,
transferred to nitrocellulose membrane, and incubated with rabbit
anti–MAT I/III (1:10,000 dilution), a generous gift from M. Pajares
(Instituto Investigaciones Biomédicas Alberto Sols, Consejo Superi-
or Investigaciones Científicas, Madrid, Spain), characterized previ-
ously (39). Membranes were incubated with peroxidase-conjugated
secondary antibodies (1:5,000 dilution; Amersham, Arlington
Heights, Illinois, USA), and bound antibody was visualized with ECL
detection (ECL; Amersham) on Kodak X-OMAT film (Eastman
Kodak, Rochester, New York, USA).
SAM/S-adenosyl-L-homocysteine (SAH), mitochondrial isolation, and GSH
determination. SAM or SAH levels were determined in liver
homogenates (or in mitochondrial fractions isolated from liver
homogenates) after homogenization with 0.5 M HClO4 followed by
neutralization of the sample with 3 M KOH. SAM/SAH levels were
determined by HPLC using a Partisil SCx 10-µm column by isocrat-
ic elution at a flow rate of 1 ml/min with 0.03 mol/l NH4H2PO4 con-
taining 2% acetonitrile, pH 2.6, as described before (33). SAM and
SAH peaks were identified at 254 nm by sample spiking with authen-
tic standards. The amount of either metabolite was calculated from
standard curves relating the peak area to calibration curves with stan-
                                                                                 
research article
The Journal of Clinical Investigation http://www.jci.org       Volume 113       Number 6       March 2004 897
dards. In some cases, mitochondria were isolated by Percoll gradient
centrifugation as described (40). GSH levels in homogenates or mito-
chondria were determined using HPLC (21, 37).
Fulminant hepatitis model and therapeutic treatment with SAM. The
combination of D-(+)-galactosamine (Gal) plus TNF-α (Gal/TNF)
or Gal plus LPS (Gal/LPS) is a known model of lethal hepatitis (41,
42). C57Bl/6 mice were used at an age of 8–10 weeks. A single dose
of recombinant murine TNF-α (10 mg/kg intravenously; Prepro-
tech EC, London, United Kingdom) or LPS (50 µg/kg intraperi-
toneally; Escherichia coli serotype 0128:B12; Sigma-Aldrich) was
administered after Gal treatment (700 mg/kg intraperitoneally),
resulting in the death of mice (90–95%) within 6–8 hours. In some
cases, SAM (p-toluensulfonate form; Europharma, Madrid, Spain)
was given hourly for 8 hours after TNF-α or LPS injection (5
mg/mouse intraperitoneally). For estimation of the effect of pro-
longed SAM treatment, SAM was administered to Gal/TNF- or
Gal/LPS-treated mice for 24 hours (hourly for the first 8 hours and
then every 8 hours). For block-
ing of GSH synthesis, L-buthio-
nine sulfoximine (BSO) was
administered (4 mmol/kg) 30
minutes before and 3 hours
after TNF-α or LPS administra-
tion. Alternatively, N-acetylcys-
teine (NAC) (30 mg/mouse
intraperitoneally) was given to
mice before treatment with
Gal/TNF or Gal/LPS to assess
the efficacy of antioxidants on
the course of liver injury. For
histology, liver specimens were
washed with PBS and embed-
ded in paraffin. Sections 7 µm
in thickness were stained with
hematoxylin and eosin using
standard methods. Serum ala-
nine aminotransferase (ALT)
and aspartate aminotransferase
levels were determined by a col-
orimetric test (Sigma-Aldrich).
TUNEL assay. Paraffin-embed-
ded liver tissue was cut into
slices 4 µm in thickness using a
microtome (Leica RM2155;
Leica Instruments, Bensheim,
Germany) and was fixed to glass
slides. The TUNEL assay was
performed by incubation of the
slices with 2 µg/ml proteinase K
(Sigma-Aldrich) in 10 mM Tris-
HCl buffer containing 5 mM
EDTA at a pH of 7.4. Sections were then labeled following the instruc-
tions of a commercial Kit (In situ Cell Death Detection Kit; Roche
Diagnostics), stained with 3,3′-diaminobenzidine (Roche Diagnos-
tics), and counterstained with hematoxylin and eosin. The slides were
mounted and examined using a Nikon Eclipse E1000 microscope.
Figure 1
Regulation of MAT1A by SMases. (A) Cultured rat hepatocytes were treated with TNF-α, with or without 
D-threo-PDMP (PDMP), or with hASMase or bNSMase alone for 16 hours. MAT1A and MAT2A mRNA lev-
els were analyzed by Northern blot and were normalized to 18S mRNA content, and the corresponding ratio
was expressed as percentage of control. The plots in the graph (bottom) are the mean ± SD of six individu-
al experiments. *P < 0.05 versus control; denotes significance for MAT1A and MAT2A changes. (B) These
experiments were similar to those shown in A except that MAT1A mRNA levels were determined by real-
time PCR analyses as described in Methods. Results are expressed as the mean ± SD of three individual
experiments. *P = 0.05 versus control. (C) MAT I/III protein content was determined by Western blot after 18
hours of incubation with TNF-α, hASMase, or bNSMase at the dose shown. Data are the mean ± SD of three
individual experiments. *P = 0.05 versus control. C, control.
Figure 2
Regulation of the effect of hASMase on MAT1A expression. Cultured rat
hepatocytes were incubated with hASMase (0.5 U/ml) for 16 hours in the
presence of bafilomycin A1 (40 nM), chloroquine (50 µM), or M 6-P (3
mM), and the levels of MAT1A, MAT2A, and 18S mRNA were analyzed
by Northern blot. The plot showing the change in the corresponding
mRNA (bottom) is the mean ± SD of three individual experiments. *P = 0.05
versus control; denotes significance for MAT1A and MAT2A changes.
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Caspase 3 and caspase 8 activation. Liver was homogenized in a buffer
containing 120 mM NaCl, 50 mM Tris-HCl, pH 7.4, 0,5 % Igepal, 2
mM ethylene glycol-bis-(β-aminoethyl ether) tetraacetic acid, and 50
µM PMSF, incubated at 4°C for 15 minutes with shaking,  and spun
down at 12,000 g at 4°C for 15 minutes. Caspase activity was assayed
with 200 µg of cell lysate and 1.25 ml of assay buffer containing 100
mM NaCl, 10% sucrose, 0.1% (3-[(3-cholamidopropyl)dimethylam-
monio]-1-propanesulfonate (CHAPS), and 10 mM DTT, pH 7.4, by
the release of 7-aminomethyl coumarin from 40 nmol of Ac-DEVD-
AMC (caspase 3) or Ac-IETD-AMC (caspase 8) (Calbiochem, San
Diego, California, USA). Fluorescence was continuously recorded
with emission at 460 nm and excitation at 380 nm as described (43).
In addition, caspase activation was also monitored by
immunoblotting using rabbit anti–caspase 3 (1:1,000 dilution;
Pharmingen, San Diego, California, USA) and anti–caspase 8 (1:100
dilution; Santa Cruz Biotechnology, Santa Cruz, California, USA) as
primary antibodies. Membranes were then incubated with peroxi-
dase-conjugated secondary antibodies (Amersham) and bound anti-
bodies were visualized as described above for MAT I/III.
Measurement of gangliosides and ceramide levels. Gangliosides levels
(including GM1, GM3, and GD3) were measured by high-perfor-
mance thin-layer chromatography as described previously (43).
Ceramide levels were quantified by HPLC (37).
TNF-α levels. Total TNF-α (bound and free) was measured in
serum after Gal/LPS treatment using a mouse-specific competitive
enzyme immunoassay kit (Chemicon, Temecula, California, USA).
Statistical analyses. Statistical analyses of mean values ± SD for
multiple comparison were made by one-way analyses of variance
followed by Fisher’s exact test. Survival curves were compared
using a log-rank χ2 test.
Results
Regulation of MAT1A by hASMase. Preservation of high levels of
MAT1A is critical for a differentiated and functional competent
liver. Upon isolation from the intact organ, cultured rat hepatocytes
undergo a gradual decline in MAT1A mRNA as it is replaced by
MAT2A mRNA (23, 44). In vitro stabilization of MAT1A, however,
can be achieved by the incubation of cultured hepatocytes with
SAM (44). Because TNF-α downregulates MAT1A expression in cul-
tured rat hepatocytes (38) and SMases mediate TNF-α signaling (8,
9), we first examined the role of individual SMases on MAT1A
expression. Cultured rat hepatocytes were incubated with exoge-
nous bNSMase and hASMase, and the levels of MAT1A and
MAT2A mRNA were examined over time. Although the intracellu-
lar levels of ceramide generated by exposure of cultured hepatocytes
to exogenous bNSMase or hASMase were equivalent (2–4 nmol
ceramide/mg cellular protein), these enzymes regulated the expres-
sion of MAT1A and MAT2A in a divergent fashion. In the presence
Figure 3
Regulation of MAT1A by sphingolipids. Cultured rat hepatocytes were
incubated for 16 hours with various sphingolipids at the concentrations
shown and the levels of MAT1A mRNA, MAT2A mRNA, and 18S mRNA
were determined by Northern blot analyses.The plot showing the change
in mRNA (bottom) is the mean ± SD of six individual experiments. *P < 0.05
versus control; denotes significance for MAT1A and MAT2A changes.
Figure 4
Regulation of MAT1A in hepato-
cytes from ASMase knockout
mice. ASMase+/+ (A) or ASMase–/–
(B) hepatocytes were cultured for
16 hours with TNF-α, bNSMase, or
hASMase at the dose shown, and
the levels of MAT1A and MAT2A
mRNA were determined by North-
ern blot. The plots (bottom) show
the mean ± SD of six to seven indi-
vidual experiments. *P < 0.05 ver-
sus control; denotes significance
for MAT1A and MAT2A changes.
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of exogenous SAM (3 mM), the level of MAT1A mRNA in control
hepatocytes remained unchanged for 14–16 hours (not shown) in
agreement with previous results (44). Next, we examined the effect
of exogenous SMases on MAT1A mRNA by Northern blot and real-
time PCR analyses. Either approach showed equivalent results, indi-
cating a decrease in the levels of MAT1A mRNA by hASMase while
those of MAT2A mRNA increased, thus mimicking the effect
observed with TNF-α (Figure 1, A and B). In contrast, exogenous
bNSMase did not affect the expression of MAT1A or MAT2A (Fig-
ure 1, A and B). The repressive effect of hASMase was observed with-
in 3 hours of incubation, with a significant reduction in MAT1A
mRNA levels to 39–45% of control values. To determine if the
downregulation of MAT1A mRNA was reflected at the protein level,
we analyzed the MAT I/III protein content by Western blot. As seen,
both TNF-α and hASMase but not bNSMase reduced the levels of
MAT I/III (Figure 1C). Consistent with these findings, we con-
firmed a severe reduction in MAT I/III enzymatic activity (8.7 ± 1.2
vs. 3.2 ± 0.8 pmol/min/mg protein in control or hASMase-treated
cells, respectively; P < 0.05). Moreover, as TNF-α increases the cel-
lular levels of glycosphingolipids synthesized in the Golgi from
ceramide, and as glycosphingolipids play an important role in cell
death (21, 43), we next examined the contribution of glycosphin-
golipids in the regulation of MAT1A by TNF-α. In agreement with
previous results (21), preincubation of cells with D-threo-PDMP
inhibited glucosylceramide synthase (GCS), the first enzyme in gly-
Figure 5
Fulminant hepatitis in ASMase+/+ and ASMase–/– mice. (A) ASMase+/+ and ASMase–/– mice (n = 25 each) were treated with Gal/TNF, and the levels of
hepatic SAM were determined over time in relation to the appearance of liver damage, as monitored by serum ALT activity in serum. *P < 0.05 versus
values at time 0; #P < 0.05 versus corresponding time points from ASMase+/+ mice. (B) Representative hematoxylin and eosin staining of liver sections
from ASMase+/+ or ASMase–/– mice collected 6 hours after treatment with Gal/TNF or Gal/LPS. Scale bars: 5 µm. (C) Caspase activity in liver samples
taken from ASMase+/+ or ASMase–/– 6 hours after treatment with Gal/TNF. *P < 0.05 versus control mice; #P < 0.05 versus ASMase+/+ mice. (D) Hepat-
ic GSH levels were determined in liver samples from ASMase+/+ and ASMase–/– mice at various times after treatment with Gal/TNF. *P < 0.05 versus
values at time 0. (E) Mitochondrial fractions were prepared from the livers of ASMase+/+ mice 6 hours after challenge with saline (C) or Gal/LPS with or
without SAM administration given hourly as described in Methods. MitGSH, mitochondrial GSH. *P < 0.05 versus control; #P < 0.05 versus Gal/LPS.
Figure 6
TUNEL assay and immunoblot analyses of caspase activation. (A) Liver
samples from ASMase+/+ or ASMase–/– mice treated with Gal/TNF or
ASMase+/+ mice treated with SAM for 8 hours were subjected to TUNEL
assay for the detection of apoptotic hepatocytes (magnification, ×200).
(B and C) Cellular extracts from these groups of mice were incubated
with anti–caspase 3 (B) or anti–caspase 8 (C) to monitor the processing
of the corresponding caspase. Representative immunoblots of three indi-
vidual experiments showing similar results are shown.
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cosphingolipid synthesis, decreasing the stimulation of GD3 and
GM1 levels by TNF-α (325% ± 56% or 298% ± 76% vs. 8% ± 5% or
3% ± 4% for GD3 and GM1 in the absence or presence of D-threo-
PDMP, respectively; P < 0.05). As expected, D-threo-PDMP enhanced
TNF-α–generated ceramide levels (2.3 ± 0.3–fold; P < 0.05). Howev-
er, under these conditions the downregulating effect of TNF-α on
MAT1A expression was not affected by D-threo-PDMP (Figure 1A).
Similar findings were observed using N-butyldeoxynojirimycin,
another GCS inhibitor (not shown). Thus, these findings show the
ability of ceramide generated specifically from hASMase to down-
regulate the expression of MAT1A and exclude the possibility of a
role for glycosphingolipids in this effect.
Abolishment of intracellular vesicle acidification prevents downregulation
of MAT1A mRNA by hASMase. We have previously shown that exoge-
nous hASMase enters hepatocytes by endocytosis being delivered
to intracellular acidic compartments (37). To assess whether hAS-
Mase requires acidic vesicles  for its effect on MAT1A expression, we
next determined the effect of lysosomotropic agents that abolish
acidification of intracellular vesicles. As shown (Figure 2),
bafilomycin A1, an inhibitor of the H+-ATPase pump responsible
for acidifying lysosomes and late endosomes (45), and chloroquine,
known to disrupt acidic compartments (46), each prevented the
downregulation of MAT1A induced by hASMase (Figure 2). More-
over, M 6-P, which blocks the delivery to endosomes/lysosomes of
enzymes via the M 6-P receptor (47), abolished the reduction in
MAT1A mRNA by hASMase (Figure 2). A similar effect for
bafilomycin A1 and chloroquine was observed in the TNF-α–medi-
ated downregulation of MAT1A mRNA levels (not shown). Thus,
these findings indicate that the internalization of hASMase into
acidic vesicles is required for the downregulation of MAT1A mRNA.
Structural requirement of ceramide in the downregulation of MAT1A. To
assess the structural requirement of ceramide, we tested the role of
sphingolipid analogs on MAT1A expression. As seen, membrane-
permeant ceramide C2, as well as glycosphingolipids GD3, GM3, lac-
tosylceramide, and glucosylceramide, reduced MAT1A mRNA levels
to a similar extent while increasing those of MAT2A (Figure 3). Sim-
ilar findings were observed for MAT1A regulation using the natural
ceramide C16 (not shown). In contrast, incubation of cells with sph-
ingomyelin, sphingosine, or dihydroceramide C2 did not change the
relative levels of MAT1A or of MAT2A mRNA. In addition, incuba-
tion of cells with lyso-lactosylceramide (Matreya) did not affect the
level of MAT1A or MAT2A mRNA (not shown). Thus, taking into
account that carbohydrates are present only in glycosphingolipids
but not in sphingolipids and that the N-fatty acyl-sphingosine moi-
ety and the trans-4,5 double bond are structural features common to
both lipid classes, it appears that the carbohydrate groups are not
required for the regulation of MAT1A expression.
TNF-α fails to downregulate MAT1A in hepatocytes from ASMase-defi-
cient mice. To assess the specific role of ASMase in the regulation of
MAT1A by TNF-α, we used hepatocytes from ASMase–/– mice, as
early signaling events in response to TNF-α are preserved in ASMase
knockout mice (21). Compared with those in ASMase+/+ cells, the lev-
els of MAT1A mRNA in hepatocytes lacking the ASMase gene were
unaffected upon exposure to TNF-α (Figure 4, A and B). However,
Figure 7
SAM therapy in fulminant hepatitis. Experimental ASMase+/+ mice (n = 40) were treated with Gal/LPS; control mice (Saline, in B; n = 40) were treated
with saline. Mice were divided in three groups: one group received SAM (5 mg/mouse intraperitoneally) or saline every hour for 8 hours after treatment
with Gal/LPS; in addition, half of the mice receiving SAM therapy were pretreated with BSO (4 mmol/kg). (A) Serum ALT or AST levels. *P < 0.05 ver-
sus Gal/LPS; #P < 0.05 versus ASMase+/+ mice treated with Gal/LPS + SAM.AST, aspartate aminotransferase. (B) Hematoxylin and eosin staining of
livers with or without SAM administration or BSO treatment. Scale bars: 5 µm. (C) Hepatocellular SAM levels of ASMase+/+ mice challenged with
Gal/LPS with or without SAM therapy. *P < 0.05 versus values at time 0; #P < 0.05 versus Gal/LPS group. (D) Caspase activity in livers from ASMase+/+
mice with or without SAM treatment. *P < 0.05 versus untreated mice; #P < 0.05 versus Gal/LPS group. (E) Hepatic GSH levels in ASMase+/+ mice
with or without SAM treatment. *P < 0.05 versus values at time 0; #P < 0.05 versus Gal/LPS group. (F) Serum TNF-α levels in ASMase+/+ mice at var-
ious time points after Gal/LPS treatment with or without SAM therapy.
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despite the unresponsiveness of ASMase–/– hepatocytes to TNF-α
exposure, the addition of exogenous hASMase markedly decreased
the levels of MAT1A mRNA while increasing those of MAT2A (Fig-
ure 4B). This effect was specific for ceramide derived from hASMase,
as incubation of cells with exogenous bNSMase did not affect
MAT1A or MAT2A mRNA content (Figure 4). These results show
that the repressive effect of TNF-α on MAT1A expression is mediat-
ed through the generation of ceramide from ASMase.
Hepatic SAM levels in ASMase–/– mice during lethal hepatitis. To address
whether the contribution of ASMase to TNF-α–induced liver injury
is through MAT1A downregulation and subsequent SAM decrease,
we examined the changes over time of hepatic SAM produced by Gal
and TNF-α or LPS in a well-established model of lethal hepatitis (41,
42). In ASMase+/+ mice (n = 25), Gal/TNF caused a time-dependent
decrease of the hepatocellular SAM levels before the occurrence of
liver damage, as monitored by the rise in ALT in serum (Figure 5A).
Histological examination of liver samples from Gal/TNF- or Gal/LPS-
treated mice indicated extensive hemorrhagic lesions with clusters of
damaged cells (Figure 5B). TUNEL assay showed the presence of
apoptotic hepatocytes in liver specimens from Gal/LPS-treated wild-
type mice (Figure 6A). In contrast, the hepatic levels of SAM in
ASMase–/– mice treated with Gal/TNF remained significantly higher
than those in wild-type mice, and this outcome was accompanied by
minimal liver damage, as monitored by serum transaminases (Figure
5A), liver histology (Figure 5B), and TUNEL assay (Figure 6A). North-
ern blot analyses indicated a decrease in MAT1A mRNA levels in
ASMase+/+ mice by 3 hours after Gal/TNF treatment (not shown). The
hepatocellular levels of SAM in the ASMase knockout mice after
Gal/TNF treatment were similar to those in ASMase+/+ mice treated
with Gal alone (63 ± 5 nmol/g liver and 53 ± 6 nmol/g liver 3 hours
and 6 hours after, respectively). As this model of liver injury is caspase
dependent, we examined the activation of caspases 8 and 3 in liver
samples after Gal/TNF administration by a fluorescence assay using
appropriate substrates and by immunoblot. Although each approach
showed activation of caspases 3 and 8 by Gal/TNF in hepatocytes
from wild-type mice (Figures 5C and 6, B and C), interestingly, cas-
pase activation was much lower in ASMase–/– mice treated with
Gal/TNF than in ASMase+/+ mice (Figures 5C and 6, B and C), sug-
gesting that ASMase is necessary for optimal caspase activation in
this model. Furthermore, as hepatic SAM regulates GSH homeosta-
sis, which in turn can modulate caspase activation (48, 49), we next
determined the time course of hepatic GSH levels in this model of
hepatocellular cell death. As seen, hepatic GSH levels decreased in
ASMase+/+ mice over time, lagging behind the reduction in SAM con-
tent in ASMase+/+ mice but not in ASMase–/– mice (Figure 5, A and D).
Similar results were observed with Gal/LPS (not shown). Finally, the
levels of mitochondrial GSH, an essential pool of GSH in the control
of mitochondrial function and cell death (21, 40), were reduced to
51 ± 7% of control levels in ASMase+/+ mice (Figure 5E).
Lethal liver failure in ASMase+/+ mice is prevented by SAM administration.
Because the fall in SAM levels was a primary event in this model of
liver failure, we next examined the therapeutic role of SAM in
ASMase+/+ mice. Initial experiments indicated that a single intraperi-
toneal injection of 10 mg/kg of SAM, a dose previously used in exper-
imental models of liver injury and fibrogenesis (33, 50), before
Gal/TNF or Gal/LPS administration was ineffective in preserving hep-
atic SAM levels and in preventing liver damage (not shown). Howev-
er, continuous SAM treatment, hourly after Gal/LPS exposure, pre-
vented liver injury through restoration of hepatic SAM (Figure 7,
A–C). Furthermore, SAM treatment decreased caspase activation, as
assessed by immunoblot (Figure 6, B and C) or stimulated fluores-
cence (Figure 7D), and these effects were accompanied by restoration
of intracellular GSH stores in cytosol (Figure 7E) and mitochondria
(Figure 5E). Indeed, the specific contribution of GSH to the protective
effect of SAM was further assessed by treatment of mice with BSO, an
inhibitor of γ-GCS. Pretreatment of ASMase+/+ mice with BSO after
Gal/LPS administration abolished the protective effect of SAM treat-
ment (Figure 7, A and B). BSO treatment, however, did not affect the
levels of SAM but prevented the recovery of GSH (not shown). In addi-
tion, to ensure that the protective effect of SAM was not due to
reduced TNF-α secretion caused by LPS, we monitored plasma
TNF-α levels over time. As seen, the time course of TNF-α appearance
in plasma was similar in Gal/LPS-treated mice with or without SAM
therapy (Figure 7F). Moreover, we checked the safety of chronic SAM
therapy in Gal/LPS-treated mice. As seen, sustained administration of
SAM was safe and devoid of side effects, as mice were protected from
Gal/LPS-induced liver damage (Figure 8A). In addition, NAC, an
antioxidant, reduced the liver injury caused by Gal/LPS (Figure 8B).
Figure 8
Protection against liver failure by chronic SAM treatment or antioxidants.
(A) ASMase+/+ mice treated with Gal/LPS were administered SAM for 16
or 24 hours, and liver damage was assessed by serum transaminase
analyses. Data are the mean ± SD of ten individual experiments. *P = 0.05
versus Gal/LPS. (B) Alternatively, ASMase+/+ mice were treated with NAC
instead of SAM to analyze its effect on liver injury induced by Gal/LPS, as
assessed by serum transaminases. Data are the mean ± SD of four indi-
vidual experiments. *P = 0.05 versus Gal/LPS.
Figure 9
Effect of SAM therapy on survival of mice treated with Gal/LPS. ASMase+/+
mice (n = 30) were treated with Gal/LPS; half were treated with SAM
(Gal/LPS + SAM) and the other half were treated with saline (Gal/LPS)
every hour for 8 hours. The percentage of dying mice was plotted as a
function of time after induction of hepatitis. *P < 0.05 vs. Gal/LPS group.
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Finally, the protective role of SAM “translated” to an improved
survival rate (Figure 9). As seen, mice (n = 15) treated with SAM were
significantly protected from lethality, compared with the control
group treated with saline. Surviving mice were still alive for at least
5 days after the Gal/LPS treatment. Treatment of mice with SAM for
24 hours resulted in a similar survival rate (not shown). Similar
results in terms of survival were observed in mice treated with
Gal/TNF instead of LPS. In addition, 80–90% of ASMase–/– mice sur-
vived at least 5 days after Gal/TNF treatment.
Discussion
The present study reveals a novel mechanism of action of ASMase
whereby this signaling enzyme promotes TNF-α–induced hepatocel-
lular damage by decreasing the expression of MAT1A. Our first
approach was the use of exogenous hASMase. Certain structural fea-
tures of this enzyme have been characterized in comparison with those
of recombinant human ASMase (51). Those studies demonstrated
that recombinant human ASMase and the native protein purified
from human placenta showed a similar glycosylation pattern and the
presence of a critical disulfide bond in the sphingolipid activator
N-terminal domain. In addition, prior studies demonstrated that
hASMase enters cells including hepatocytes via M 6-P receptor–medi-
ated endocytosis and is delivered into acidic compartments (37, 47,
52). Consistent with the pH optima of hASMase, we verified that
agents that block intracellular vesicle acidification abolished the effect
of hASMase on MAT1A expression. In addition, the action of hAS-
Mase on MAT1A expression was prevented by an excess of M 6-P,
which would be expected to compete with hASMase for endocytosis
without dissipating the pH gradient of acidic intracellular compart-
ments. Thus, based on these findings it appears that endocytosis of
hASMase and its delivery into acidic vesicles where the enzyme
becomes active are required for the downregulation of MAT1A expres-
sion. However, the precise intracellular site where hASMase becomes
activated remains to be identified. In addition to this approach, we
also used hepatocytes deficient in ASMase–/–. The data we obtained
show the resistance of hepatocytes from ASMase knockout mice to
TNF-α–induced downregulation of MAT1A. However, the levels of
MAT1A mRNA were reduced by hASMase, indicating that the
response of hepatocytes from ASMase knockout mice to TNF-α in the
regulation of MAT1A is dependent on the presence of ASMase.
An important implication from these results is the divergent func-
tions of NSMase versus ASMase in the regulation of MAT1A expres-
sion. Not only did bNSMase, a Mg2+-dependent exogenous SMase at
neutral pH, characterized previously (8, 9, 37), fail to affect the expres-
sion of MAT1A, but also, more importantly, the activation of
NSMase by TNF-α remains intact in hepatocytes from ASMase
knockout mice (21) and yet in ASMase–/– hepatocytes, TNF-α failed
to downregulate MAT1A. Thus, our findings clearly indicate that the
ceramide pool signaling the downregulation of MAT1A originates
from an acidic intracellular compartment, whereas the ceramide pool
derived from NSMase is inactive, illustrating that the role of ceramide
in cell signaling depends on the specific SMase activated. This out-
come regarding the effect of ASMase on gene regulation contrasts
with previous reports discarding a role for ceramide produced in lyso-
somes in apoptosis signaling. For instance, stress-induced apoptosis
was observed in Epstein-Barr virus–transformed B lymphocytes from
control individuals as well as from patients affected with Niemann-
Pick disease, an autosomal recessive condition characterized by defi-
cient ASMase in lysosomes (14). In contrast, DeMaria et al. (52), who
also used Niemann-Pick lymphoblast lines, concluded that ASMase
was required for Fas-mediated apoptosis. On the other hand, hepa-
tocytes deficient in ASMase have been shown to be resistant to ion-
izing radiation–, Fas- or TNF-α–mediated cell death (15, 19–21). Fur-
thermore, consistent with our findings regarding MAT1A regulation,
Monney et al. (53) reported that agents that alkalinize acidic vesicles
attenuate TNF-α–induced apoptosis in U937 human monocytes and
L292 mouse fibroblasts. Thus, it appears that the role of individual
SMases in signaling pathways (apoptosis or gene regulation) depends
on several conditions, such as the stimuli used and type of cell stud-
ied. Hence, taken collectively, our data establish that MAT1A is selec-
tively downregulated by ceramide generated from the activation of
ASMase in acidic intracellular compartments, which mediates the
effects observed with TNF-α.
Of note, we would like to emphasize that the downregulating effect
of TNF-α or hASMase on MAT1A mRNA levels was observed despite
the presence of exogenous SAM, which stimulates the transcription
of MAT1A (44). Thus, in further examining the putative mechanism
involved in the downregulation of MAT1A by ASMase, we deter-
mined the stability of MAT1A mRNA in the presence of actinomycin
D. Our data show that the presence of hASMase shortened the half-life
of MATA1 mRNA from 5.4 ± 0.3 hours to 3.3 ± 0.2 hours (P = 0.005).
In an attempt to characterize this process further, we observed that
cycloheximide pretreatment abolished the effect of hASMase on
MAT1A mRNA decay, suggesting the involvement of specific pro-
teins. Thus, although at present we do not understand the mecha-
nism involved in the posttranscriptional decay of MAT1A mRNA by
ASMase, an important pathway in the control of mRNA includes the
recruitment of the exosome by AU-binding proteins to affect 3′-to-5′
mRNA degradation (54). Although clearly more work will be required
to fully characterize this novel mechanism in the regulation of
MAT1A expression by ASMase-induced ceramide generation, includ-
ing the identification of the specific proteins involved and the role of
the AU site in the 3′ untranslated region of MAT1A, similar effects on
the modulation of mRNA stability have been described recently for
Figure 10
Scheme depicting the mechanisms used by ASMase in mediating the
cytotoxic effects of TNF-α. Our present findings illustrate the conse-
quences of the downregulation of MAT1A by ASMase resulting in GSH
depletion, particularly in the mitochondria, subsequent to the decrease
in SAM levels. Although this mechanism leaves hepatocytes unprotect-
ed, glycosphingolipids, especially GD3, synthesized from the pool of
ceramide generated by ASMase activation, increase and traffic to the
mitochondria, initiating the apoptosome activation responsible for hep-
atocellular apoptosis and liver failure. Both processes promote the dam-
aging effects induced by TNF-α. SAM treatment would replenish GSH
stores, including those in mitochondria (Mit), producing favorable con-
ditions in which hepatocytes withstand the effects of TNF-α.
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cell-permeable ceramides in other cell types. For instance, in Jurkat
cells, ceramide C2 shortened the half-life of Bcl-2 mRNA through a
conserved AU-rich element in the 3′ untranslated region of Bcl-2
mRNA (55). In addition, other remaining questions include how
ceramide recruits or activates this regulated pathway (54). Whether
ceramide generated within acidic vesicles undergoes a transbilayer
movement similar to what has been recently reported for bNSMase
(56) in erythrocyte ghosts remains to be established. In hepatocytes
we have shown that the ceramide pool generated from bNSMase
must undergo a “flip-flop” movement across the bilayer to signal the
transcriptional regulation of genes such as γ-GCS (37).
To examine the in vivo consequences of the downregulation of
MAT1A by ASMase, we analyzed the regulation of hepatic SAM
during the progression of liver failure in a model of lethal hepati-
tis. This approach revealed that the depletion of hepatocellular
SAM levels precedes the activation of caspases induced by TNF-α,
resulting in liver damage and lethality. The outcome of ASMase–/–
mice challenged with Gal/TNF was similar to that of ASMase+/+
mice treated with Gal alone. In both cases, the mild decrease in hep-
atic SAM reflects the effect of Gal, a hepatotoxin that blocks tran-
scription in hepatocytes. MAT I/III is sensitive to oxidative stress
due to the targeting of a critical cysteine residue (30, 32). Hence the
downregulation of MAT1A and the inactivation of MAT I/III accel-
erate the depletion of SAM by TNF-α in ASMase+/+ mice, initiating
a cascade of events that culminate in the death of mice. As shown
by TUNEL assay, the fulminant outcome of this model reflects a
prominent hepatocellular apoptosis. In comparing caspase activa-
tion in ASMase–/– versus ASMase+/+ mice, we unexpectedly observed
a defective activation of caspase 8 by TNF-α in ASMase knockout
mice. Previous findings reported the involvement of upstream cas-
pases, such as caspase 8, in the activation of ASMase (57–59); how-
ever, our data indicate that ASMase is needed for optimal caspase
8 activation by TNF-α (Figure 5C) and suggest an inverse hierar-
chical ordering in caspase 8/ASMase activation, as reported for Fas
(58, 59). This effect seems to be dependent on SAM through replen-
ishment of GSH levels, as SAM therapy attenuated caspase 8 acti-
vation in ASMase+/+ mice (Figure 7D). Furthermore, our findings
also indicate the regulation of caspase 3 by ASMase. In the absence
of ASMase, we observed a lowered activation of caspase 3 by TNF-α
(Figures 5C and 6B), and this ASMase-independent caspase 3 acti-
vation may be due to the participation of other signaling proteins,
such as cathepsin B (5). In addition, SAM seems to regulate caspase
3 activation. This outcome may reflect the ability of SAM to regu-
late the mitochondrial commitment to cell death (60, 61). Deple-
tion of SAM in the livers of MAT1A–/– knockout mice has been
shown to modulate mitochondrial integrity through regulation of
the expression of prohibitin, a protein encoded in the nucleus that
participates in the functional organization of mitochondria (60).
However, in addition to this potential mechanism, it is likely that
the protective effect of SAM in lethal hepatitis is dependent on the
replenishment of GSH levels, particularly in mitochondria (39, 62),
as BSO pretreatment abrogated the therapeutic role of SAM.
Indeed, mitochondrial GSH has been shown to play an essential
role in the survival of hepatocytes in the face of TNF-α–mediated
cell death (21, 37, 40, 62).
The present study complements recent observations on the mech-
anisms of TNF-α–induced hepatocellular damage (21) (Figure 10).
Through MAT1A downregulation and subsequent SAM decrease,
mitochondrial GSH levels become limited, leaving hepatocytes
unprotected from death signals generated by TNF-α–induced
ASMase activation, such as GD3 (21). As GD3 can target mitochon-
dria (63), the consequences of this interaction, which leads to apop-
tosome assembly and caspase 3 activation, depend largely on the lev-
els of mitochondrial GSH (21, 43, 63). Thus, the combination of
mitochondrial GSH depletion and the trafficking of GD3 to mito-
chondria mediates the hepatocellular damage of TNF-α. An impli-
cation of the current and previous findings (21) is that in addition
to the therapeutic effect of SAM, interference with ASMase signal-
ing may be beneficial, as it would spare SAM/GSH levels and avoid
the production of harmful lipids such as GD3. The effects of
ASMase inhibitors in vivo on liver function and protection against
liver failure remain to be established, however.
Taken together, our findings characterize a novel function of
ASMase in the cytotoxicity of TNF-α. Given that TNF-α is essential
in several forms of liver damage, such as alcohol-induced liver injury
(31, 40) and lethal hepatitis (41, 42), our findings may be of thera-
peutic relevance for the prevention of fulminant liver failure and the
treatment of liver diseases through replenishment of SAM and sub-
sequent restoration of mitochondrial GSH.
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